Ambu A/S (OTCMKTS:AMBBY) Shares Gap Down - Here's Why

Key Points

• Ambu A/S shares gapped down from a previous close of $16.78 to open at $15.68, with the last trade recorded at $15.64 and a volume of 800 shares.
• The company reported $0.07 earnings per share for its most recent quarter, with a revenue of $229.16 million and a net margin of 5.93%.
• Ambu A/S has a market capitalization of $3.67 billion and maintains a low debt-to-equity ratio of 0.08, indicating a strong financial position.

Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.78, but opened at $15.68. Ambu A/S shares last traded at $15.64, with a volume of 800 shares changing hands.

Ambu A/S Stock Performance

The stock has a 50-day simple moving average of $15.30 and a 200-day simple moving average of $15.64. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 82.32 and a beta of 0.83. The company has a current ratio of 2.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last announced its earnings results on Friday, August 22nd. The company reported $0.07 earnings per share (EPS) for the quarter. Ambu A/S had a return on equity of 6.11% and a net margin of 5.93%.The company had revenue of $229.16 million for the quarter.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.